chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Urticaria
Clinical narrative: Hives or red rash torso, front and back, down arms and groin - not itchy; Fever; Body aches; Chills; Fatigue; Headache; This is a spontaneous report from a contactable other healthcare professional, the patient. A 61-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 30Mar2021 at 13:00(at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included moderate and controlled asthma and environmental allergy. Concomitant medications included allergy shots taken monthly. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number:EN6205) via an unspecified route of administration in the left arm on 10Mar2021 (at the age of 61-years-old) as a single dose for COVID-19 immunisation.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 16:00 the patient experienced  within 3 hours of Pfizer booster(second dose), chills, headache, fatigue. The patient woke up on 31Mar2021 with fever(100.2), exhaustion, body aches, chills, headache. The patient woke up on 01Apr2021 with red rash/hives all over her torso, front and back, down her arms, and in groin which was not itchy. All other symptoms continued. The next day, 02Apr2021 was same as the last day. On 03Apr2021 the patient experienced the first day without  headache, chills, fever, exhaustion and hives were fading. Therapeutic measures were taken as a result of the reported adverse events and included treatment with Tylenol, 650 mg every 4 hours started on 30March2021 to 02Apr2021(4 days). Lab test included body temperature on 30Mar2021 and the result was 100.2. The clinical outcome of the events headache, chills, fever and exhaustion was recovered on 03Apr2021. The clinical outcome of the events hives and body aches were recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache I never get headaches and my head began to ache the next day- it subsided and is gone now but I had a fairly good headache; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Apr2021 at 09:15 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications taken within two weeks of vaccination included olmesartan (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 08:00 the patient experienced headache. The patient never gets headaches and his head began to ache the next day- it subsided and was gone at the time of report but the patient had a fairly good headache. The patient did not receive any treatment for the event. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache was recovered on an unknown day in Apr2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Dizziness, Headache, Nausea
Clinical narrative: Fever(99.9); body aches; Chills; nausea; Lightheadedness; Headache; Headache, red, raised, tender, hot injection site; Headache, red, raised, tender, hot injection site; Headache, red, raised, tender, hot injection site; hot injection site; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 14:00 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications included ketoprofen (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA), fluticasone propionate (FLONASE), multivitamin (MANUFACTURER UNKNOWN) and wellness (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received morphine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced allergy. On 03Apr2021 at 10:00, the patient experienced fever (99.9), body aches, chills, nausea, lightheadedness, headache, red, raised, tender, hot injection site. On 03Apr2021, the patients body temperature was reported as 99.9 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported events and included treatment with ibuprofen on unknown date. The clinical outcome of the events fever (99.9), body aches, chills, nausea, lightheadedness, headache, red, raised, tender, hot injection site was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Fever(99.9); body aches; Chills; nausea; Lightheadedness; Headache; Headache, red, raised, tender, hot injection site; Headache, red, raised, tender, hot injection site; Headache, red, raised, tender, hot injection site; hot injection site; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 14:00 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications included ketoprofen (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA), fluticasone propionate (FLONASE), multivitamin (MANUFACTURER UNKNOWN) and wellness (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received morphine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced allergy. On 03Apr2021 at 10:00, the patient experienced fever (99.9), body aches, chills, nausea, lightheadedness, headache, red, raised, tender, hot injection site. On 03Apr2021, the patients body temperature was reported as 99.9 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported events and included treatment with ibuprofen on unknown date. The clinical outcome of the events fever (99.9), body aches, chills, nausea, lightheadedness, headache, red, raised, tender, hot injection site was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site warmth
Clinical narrative: Fever(99.9); body aches; Chills; nausea; Lightheadedness; Headache; Headache, red, raised, tender, hot injection site; Headache, red, raised, tender, hot injection site; Headache, red, raised, tender, hot injection site; hot injection site; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 14:00 (at the age of 35-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date. Concomitant medications included ketoprofen (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA), fluticasone propionate (FLONASE), multivitamin (MANUFACTURER UNKNOWN) and wellness (MANUFACTURER UNKNOWN), all from unknown dates for unknown indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received morphine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced allergy. On 03Apr2021 at 10:00, the patient experienced fever (99.9), body aches, chills, nausea, lightheadedness, headache, red, raised, tender, hot injection site. On 03Apr2021, the patients body temperature was reported as 99.9 (units unspecified). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of reported events and included treatment with ibuprofen on unknown date. The clinical outcome of the events fever (99.9), body aches, chills, nausea, lightheadedness, headache, red, raised, tender, hot injection site was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Breast swelling
Clinical narrative: Swelling of breast tissue under left arm; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 13:00 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included type 2 diabetes mellitus, blood pressure high, anxiety and depression. The patient did not have a history of allergies to medications, food, or other products. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the left arm on 12Mar2021 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Concomitant medications included metformin (MANUFACTURER UNKNOWN), ergocalciferol (VITAMIN D2), rosuvastatin calcium (CRESTOR) and lisinopril (MANUFACTURER UNKNOWN), all for unknown indication. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 03Apr2021 at 13:00, the patient experienced swelling of breast tissue under left arm. The patient did not receive any treatment for the reported event. Adverse event did not result in doctor or other healthcare professional office or clinic visit, and emergency room or department or urgent care. The clinical outcome of the event swelling of breast tissue under left arm was not resolved at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Insomnia, Myalgia, Nausea
Clinical narrative: Insomnia; achy joints; achy muscles; chills; bit of nausea; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm  on 12Mar2021 at 08:00 (at the age of 69-year-old) as a single dose for COVID-19 immunisation. Patient did not had any medical history. Concomitant medications included ergocalciferol, calcium phosphate and calcium sodium lactate (CALCIUM WITH VITAMIN D), acetylsalicylic acid (BABY ASPIRIN) and Curcuma longa (TURMERIC),  all for unknown indications from an unknown date. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Feb2021 at 07:00 (at the age of 69-year-old) as a single dose for COVID-19 immunisation. The patient did not had any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Mar2021,  three days after the second shot, the patient experienced insomnia, achy joints and muscles, chills and a bit of nausea.  The patient did not receive any treatment for the reported  events. The clinical outcome of the events of insomnia, aching joints, muscle ache, chills and nausea was recovered on an unknown date.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Extreme pain and swelling in lymph under right arm; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Apr2021 at 14:00 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history included seasonal allergy, asthma and osteoarthritis. The patient was allergic to iodine dye. Concomitant medications included ranitidine hydrochloride (ZANTAC), omeprazole (PRILOSEC), bupropion hydrochloride (WELLBUTRIN), desvenlafaxine succinate monohydrate (PRISTIQ) and gabapentin (MANUFACTURER UNKNOWN), all taken from unknown dates for unknown indications. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 12Mar2021 at 14:00 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. On 03Apr2021 at 09:00, the patient experienced extreme pain and swelling in lymph under right arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event experienced. The clinical outcome of the event extreme pain and swelling in lymph under right arm was not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain in extremity, Pyrexia, SARS-CoV-2 test
Clinical narrative: sore arm for first 24 hours; nausea; low grade fever; This is a spontaneous report from a non-contactable consumer, the patient. A 54-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the arm right on 31Mar2021 at 10:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma from an unknown date. Concomitant medications of the patient were not reported. Patient previously received diphenhydramine (BENADRYL), oxycodone; acetaminophen (PERCOCET) all from an unknown date for an unspecified indication and experienced allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient underwent a COVID-19 virus test, nasal swab on 20Dec2020, result of which was negative. On 03Apr2021 at 16:00 the patient experienced sore arm for first 24 hours, nausea and low-grade fever. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Clinical outcome of pain in arm, nausea, low grade fever was unknown at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Extreme fatigue, hard to get out of bed; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the left arm on 25Mar2021 at 15:30 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had known allergies to bell peppers and other sweet peppers. Concomitant medications included vitamin d (MANUFACTURER UNKNOWN), fluticasone propionate (FLONASE) and iron supplement; all from unknown date for unknown indication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021, the patient experienced extreme fatigue, hard to get out of bed the next day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcomes of extreme fatigue, hard to get out of bed were resolved on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Disorientation, Dizziness, SARS-CoV-2 test
Clinical narrative: Severe dizziness; Disorientation; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 03Apr2021 at 14:00 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. The patient was allergic to seafood allergy. The patient reported no other medical history. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19.  On 02Apr2021, the patient underwent rapid and Polymerase Chain Reaction (PCR) test (nasal swab) and the result was negative. On 03Apr2021 at 14:05, 5 minutes after the vaccination, the patient experienced severe dizziness and disorientation. It had not been 3 hours and he was still dizzy and disoriented. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events severe dizziness and disorientation was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Axillary pain, Inappropriate schedule of product administration, Pain in extremity
Clinical narrative: Swollen armpit; Left armpit became very painful to the touch; Left arm was sore; Inappropriate schedule of vaccine administered; This is a spontaneous report from a contactable consumer, the patient. A 29-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the arm left on 31Mar2021 (at the age of 29-years-old) as a single dose for COVID-19 immunisation (Inappropriate schedule of vaccine administered). Medical history included swollen lymph nodes and breast cancer (reported as both sides of her family have breast cancer and issues with lymph nodes swelling). Patient received other medications in two weeks which included azurette (MANAFACTURER UNKNOWN) from an unspecified date for an unknown indication. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the arm left on 14Mar2021 at 16:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had no known allergies. On 31Mar2021, the patient experienced inappropriate schedule of vaccine administered, and on 01Apr2021 at 20:00, the patient experienced left arm was sore. Within 24 hours of receiving the shot, left armpit became very painful to the touch and was swollen. It had been 2 full days and it was still very painful. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Clinical outcomes of events axillary mass, armpit pain, pain in arm was not recovered. While, it was unknown for inappropriate schedule of vaccine administered.  No follow-up attempts are needed. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Urticaria
Clinical narrative: Rash on the right forearm; Hives on inner thighs progressed to outer thigh and hips, then belly, and on arms; Really bad itching; This is a spontaneous report from a contactable other healthcare professional, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6207) via an unspecified route of administration in the left arm on 30Mar2021 at 13:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included scleroderma, fibromyalgia, raynauds, pulmonary hypertension and other unspecified conditions. The patient was allergic to other unspecified medications. The patient received unspecified medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received flu vaccine and experienced rashes and hives. It was unknown whether prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 30Mar2021 at 14:00, right after the vaccination, the patient experienced rash on the right forearm and then hives on her inner thighs which progressed to her outer thigh and hips, then belly and on arms. The patient also experienced really bad itching. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event rash on the right forearm, hives on inner thighs progressed to outer thigh and hips, then belly and on arms and really bad itching was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Lymphadenopathy, Myalgia
Clinical narrative: Chills; Fever; Muscle aches; Headache; General fatigue; Nausea; Lymph node discomfort; This is a spontaneous report from a contactable consumer, the patient. A 62-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 02Apr2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included bronchitis asthmatic from an unspecified date. Patient received other medications in two weeks which included fluoxetine hydrochloride (PROZAC) from an unspecified date for an unknown indication. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 12Mar2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had no known allergies. On 02Apr2021 at 22:00 the patient experienced chills, fever, muscle aches, headache, general fatigue, nausea and lymph node discomfort. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of chills, fever, muscle aches, headache, fatigue, nausea and lymph node disorder were not recovered at the time of reporting.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pyrexia
Clinical narrative: Chills; Fever; Muscle aches; Headache; General fatigue; Nausea; Lymph node discomfort; This is a spontaneous report from a contactable consumer, the patient. A 62-years-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 02Apr2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history included bronchitis asthmatic from an unspecified date. Patient received other medications in two weeks which included fluoxetine hydrochloride (PROZAC) from an unspecified date for an unknown indication. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 12Mar2021 at 12:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient had no known allergies. On 02Apr2021 at 22:00 the patient experienced chills, fever, muscle aches, headache, general fatigue, nausea and lymph node discomfort. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of chills, fever, muscle aches, headache, fatigue, nausea and lymph node disorder were not recovered at the time of reporting.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 63.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Myalgia, Peripheral swelling
Clinical narrative: severe swelling in both hands; moderate joint pain; moderate muscle pain; fatigue; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0259, expiration date: an unknown date in Jul2021) via an unspecified route of administration in the left arm on 01Apr2021 at 14:00 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. Medical history of the patient included osteoarthritis. Patient did not have any allergies to food, medications or other products. Concomitant medications included sildenafil citrate (VIAGRA) 100mg from an unknown date for unknown indication, bupropion XL 400mg (MANUFACTURER UNKNOWN) from an unknown date for unknown indication, and vortioxetine hydrobromide 10 (TRINTELLIX) from an unknown date for unknown indication. It was unknown if prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to COVID vaccine. On 03Apr2021, the patient experienced severe swelling in both hands, moderate joint pain, moderate muscle pain and fatigue. Therapeutic measures were taken as a result of adverse events and included treatment with Ibuprofen (MANUFACTURER UNKNOWN) 600 mg x 1 time. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events severe swelling in both hands, moderate joint pain, moderate muscle pain and fatigue were unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Headache, Nausea, Pain, Vaccination site pain
Clinical narrative: feeling a little hazy; Blurred vision; general weakness; minor aches; nausea; body aches; slight headache; soreness in injection site; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 30Mar2021 at 08:30 (at the age of 66-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetic type 2 controlled and Psoriasis. The patient was allergic to cucumbers. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), tiagabine (MANUFACTURER UNKNOWN) and meloxicam (MANUFACTURER UNKNOWN) and seven more medication, all for unknown indication and from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203), via an unspecified route of administration in the left arm on 09Mar2021 at 08:45 (at the age of 66-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 13:00, the patient experienced slight headache and soreness in injection site(vaccination site pain). On 31Mar2021 the patient experienced headache, nausea and body aches. On 01Apr2021 the patient experienced vision impaired(blurred vision), slight headache, slight nausea general weakness and minor aches. On 02Apr2021 the patient felt slight headache, slight nausea, slight weakness. On 03Apr2021 the patient felt little hazy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events slight headache, slight soreness in injection site, nausea, body aches, vision impaired(blurred vision), general weakness, minor aches and feeling a little hazy were recovered with sequelae.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: feeling a little hazy; Blurred vision; general weakness; minor aches; nausea; body aches; slight headache; soreness in injection site; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 30Mar2021 at 08:30 (at the age of 66-year-old) as a single dose for COVID-19 immunisation. Medical history included diabetic type 2 controlled and Psoriasis. The patient was allergic to cucumbers. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), tiagabine (MANUFACTURER UNKNOWN) and meloxicam (MANUFACTURER UNKNOWN) and seven more medication, all for unknown indication and from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6203), via an unspecified route of administration in the left arm on 09Mar2021 at 08:45 (at the age of 66-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 30Mar2021 at 13:00, the patient experienced slight headache and soreness in injection site(vaccination site pain). On 31Mar2021 the patient experienced headache, nausea and body aches. On 01Apr2021 the patient experienced vision impaired(blurred vision), slight headache, slight nausea general weakness and minor aches. On 02Apr2021 the patient felt slight headache, slight nausea, slight weakness. On 03Apr2021 the patient felt little hazy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events slight headache, slight soreness in injection site, nausea, body aches, vision impaired(blurred vision), general weakness, minor aches and feeling a little hazy were recovered with sequelae.   No follow-up attempts are needed. No further information is expected.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Pain, Pruritus
Clinical narrative: Itching; Pain; Shingles; This is a spontaneous report from a contactable consumer, the patient. A 68-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6205) via an unspecified route of administration in the arm left on 19Mar2021 at 09:00 (at the age of 68-years-old) as a single dose for COVID-19 immunisation. Medical history included shingles in Nov2020 and obesity. Concomitant medications included ibuprofen (MANUFACTURER UNKNOWN) from unknown date for unknown indication. Patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 after receiving vaccine, the patient had shingles pain and itching. The patient did not received any treatment for reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events shingles, itching and pain was not recovered.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Fatigue
Clinical narrative: Tiredness; This is a spontaneous report from a contactable consumer. A male patient of unknown age received unspecified dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration on 29Mar2021, as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. On 30Mar2021 the patient experienced tiredness. The clinical outcome of the event tiredness was unknown.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature decreased, Diarrhoea, Dizziness, Headache
Clinical narrative: Dizzy; Severe headache; Nausea; Severe diarrhea; Low Body Temperature 95.9 degrees; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: cpt1533) via an unspecified route of administration in the left arm on 01Apr2021 at 10:45 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus, minimal change disease and asthmatic. Concomitant medications included insulin (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN). The patient's allergies to medications, food or other products included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 04:15, the patient experienced dizzy, severe headache, nausea, severe diarrhea, low body temperature 95.9 degrees. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events dizzy, severe headache, nausea, severe diarrhea and low body temperature 95.9 degrees were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea
Clinical narrative: Dizzy; Severe headache; Nausea; Severe diarrhea; Low Body Temperature 95.9 degrees; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: cpt1533) via an unspecified route of administration in the left arm on 01Apr2021 at 10:45 (at the age of 56-year-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus, minimal change disease and asthmatic. Concomitant medications included insulin (MANUFACTURER UNKNOWN) and losartan (MANUFACTURER UNKNOWN). The patient's allergies to medications, food or other products included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 04:15, the patient experienced dizzy, severe headache, nausea, severe diarrhea, low body temperature 95.9 degrees. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events dizzy, severe headache, nausea, severe diarrhea and low body temperature 95.9 degrees were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspepsia, Rash
Clinical narrative: Heart burn; Rash all over body; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the arm left on 30Mar2021 at 12:00 (at the age of 43-years-old), as a single dose for COVID-19 immunisation. Medical history included diabetic. The patient did not have any allergies to medications, food or other products. Concomitant medications included unspecified diabetic medicine from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021 at 17:00, the patient experienced rash all over body and heart burn. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events rash all over body and heart burn were resolved with sequelae at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Developed an internal itching on right thigh; This is a spontaneous report from a contactable consumer, the patient. A 67-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in left arm on 19Mar2021 at 12:00 (at the age of 67-years-old) as single dose for COVID-19 immunisation. Medical history of the patient included allergy to penicillin, sulfa drugs from an unspecified date. Patient received other medications in two weeks, names were unspecified. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613) via an unspecified route of administration in left arm on 26Feb2021 at 10:00 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 22Mar2021 at 09:00, patient developed an internal itching on her right thigh which persisted for over a week. Patient reported to have scratched it and raised a black and blue mark on thigh as a result. Localized to upper right thigh. Patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Clinical outcome of itching was recovering at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Nausea, Pain
Clinical narrative: Body aches,; Fatigue; Nausea; This is a spontaneous report from a non-contactable consumer, the patient. A 42-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration in the arm left on 30Mar2021 at 10:00 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included paroxetine (MANUFACTURER UNKNOWN) from unknown date, for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. On 31Mar2021 at 08:00, the patient experienced body aches, fatigue and nausea. No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events body aches, fatigue and nausea was not recovered.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chest pain, Chills, Dyspnoea, Feeling hot
Clinical narrative: Chest tightening; Chills; Heat all over the injected arm; Sweating; Hand shaking (on injected arm); Difficultly breathing; Nauseous; Lingering chest pain; Heat all over the injected arm, chest and head area; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP 9655) via an unspecified route of administration in the left arm on 02Apr2021 at 14:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple allergies and pollen allergy. Concomitant medications included mometasone furoate (FLONASE) and cetirizine hydrochloride (ZYRTEC); both taken for allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 21:00, the patient experienced chest tightening, chills, heat all over the injected arm, chest and head area, sweating, hand shaking (on injected arm), difficultly breathing, nauseous and lingering chest pain. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events chest tightening, chills, heat all over the injected arm, chest and head area, sweating, hand shaking (on injected arm), difficultly breathing, nauseous and lingering chest pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Nausea, Tremor, Vaccination site warmth
Clinical narrative: Chest tightening; Chills; Heat all over the injected arm; Sweating; Hand shaking (on injected arm); Difficultly breathing; Nauseous; Lingering chest pain; Heat all over the injected arm, chest and head area; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP 9655) via an unspecified route of administration in the left arm on 02Apr2021 at 14:45 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history included multiple allergies and pollen allergy. Concomitant medications included mometasone furoate (FLONASE) and cetirizine hydrochloride (ZYRTEC); both taken for allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 03Apr2021 at 21:00, the patient experienced chest tightening, chills, heat all over the injected arm, chest and head area, sweating, hand shaking (on injected arm), difficultly breathing, nauseous and lingering chest pain. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events chest tightening, chills, heat all over the injected arm, chest and head area, sweating, hand shaking (on injected arm), difficultly breathing, nauseous and lingering chest pain was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.